LOG IN
SIGN UP
MARKET
MDGL
MDGL
Madrigal Pharmac
NASDAQ
65.24
-2.12
-3.15%
After Hours: 66.00 +0.76 +1.16% 19:18 12/08 EST
OPEN
67.36
PREV CLOSE
67.36
HIGH
70.46
LOW
64.19
VOLUME
339.28K
TURNOVER
0
52 WEEK HIGH
105.93
52 WEEK LOW
52.33
MARKET CAP
1.12B
P/E (TTM)
-4.0712
1D
5D
1M
3M
1Y
5Y
Madrigal Pharmaceuticals: Q3 Earnings Insights
Benzinga · 11/03 14:11
Madrigal Pharmaceuticals GAAP EPS of -$4.75 misses by $0.61
Seekingalpha · 11/03 12:59
BRIEF-Madrigal Pharmaceuticals Provides An Overview Of Upcoming Resmetirom Data Presentations
Reuters · 11/03 12:34
-- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q3 Loss $-4.75
-- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q3 Loss $-4.75
MT Newswires · 11/03 08:15
A Chronic Disease Still Waiting for a Drug
As biotech companies take new shots at fatty liver disease, investor skepticism and potential payoffs are high.
The Wall Street Journal · 09/20 13:03
BRIEF-Madrigal Pharma Initiates Maestro-Nash Outcomes Study Testing Resmetirom For Treating Patients With Compensated Nash Cirrhosis
BRIEF-Madrigal Pharma Initiates Maestro-Nash Outcomes Study Testing Resmetirom For Treating Patients With Compensated Nash Cirrhosis
Reuters · 08/31 12:19
Madrigal Pharmaceuticals Initiates The MAESTRO-NASH Outcomes Study Evaluating Resmetirom For The Treatment Of Patients With Compensated NASH Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced initiation of the “MAESTRO-NASH
Benzinga · 08/31 12:06
Madrigal Pharmaceuticals Starts Liver Disease Study of Resmetirom
Madrigal Pharmaceuticals Starts Liver Disease Study of Resmetirom
MT Newswires · 08/31 10:30
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.